Senseonics Holdings Inc (NYSEAMERICAN:SENS) – Investment analysts at Svb Leerink decreased their Q1 2019 earnings per share (EPS) estimates for shares of Senseonics in a report issued on Tuesday, March 12th. Svb Leerink analyst D. Antalffy now expects that the company will post earnings per share of ($0.06) for the quarter, down from their previous forecast of ($0.05). Svb Leerink also issued estimates for Senseonics’ Q3 2019 earnings at ($0.07) EPS, FY2019 earnings at ($0.25) EPS, Q1 2020 earnings at ($0.05) EPS, Q3 2020 earnings at ($0.07) EPS, Q4 2020 earnings at ($0.07) EPS, FY2020 earnings at ($0.24) EPS and FY2021 earnings at ($0.20) EPS.
Senseonics (NYSEAMERICAN:SENS) last issued its quarterly earnings results on Tuesday, March 12th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.11. The firm had revenue of $7.20 million for the quarter, compared to analysts’ expectations of $7.89 million.
NYSEAMERICAN:SENS opened at $2.65 on Friday. Senseonics has a 52-week low of $2.15 and a 52-week high of $5.29.
Hedge funds have recently modified their holdings of the stock. Amalgamated Bank purchased a new stake in Senseonics during the 4th quarter valued at about $28,000. First Allied Advisory Services Inc. purchased a new stake in Senseonics during the 4th quarter valued at about $35,000. Great West Life Assurance Co. Can purchased a new stake in Senseonics during the 4th quarter valued at about $41,000. Frontier Investment Mgmt Co. purchased a new stake in Senseonics during the 4th quarter valued at about $52,000. Finally, Cerity Partners LLC boosted its holdings in Senseonics by 33.3% during the 4th quarter. Cerity Partners LLC now owns 20,000 shares of the company’s stock valued at $52,000 after acquiring an additional 5,000 shares during the period. Institutional investors own 30.66% of the company’s stock.
Senseonics Company Profile
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Recommended Story: Understanding Specialty Certificates of Deposit
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.